Kezar Life Sciences Inc

Healthcare · Biotechnology

0.175$ +6.1% vs. previous close Closing price · As of: Aug 13, 2026

Statements

Balance Sheet

Kezar Life Sciences Inc (KZR) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q1 26), "Total Assets" came in at 68 million $. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

Tick rows to compare them in a chart (up to 4)

Balance Sheet KZR
Line item	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26
Total Assets	11	–	–	–	54	54	126	120	115	113	105	98	90	135	168	161	152	152	140	131	218	252	318	305	300	284	263	249	221	199	180	164	145	125	109	98	77	68
Current Assets	10	9.7	–	–	52	50	121	115	110	104	96	89	81	127	161	154	145	146	133	125	212	246	311	299	286	265	244	231	207	186	168	156	137	120	105	95	76	68
Cash	9.7	-9.7	–	–	51	47	102	40	24	18	13	20	15	21	17	13	21	23	26	57	63	39	105	64	40	36	28	26	35	33	28	35	42	37	34	39	72	66
Cash & Short-Term Investments	–	9.7	–	–	51	47	118	113	107	101	93	85	78	123	157	150	140	142	129	121	208	243	307	290	277	258	237	218	201	180	164	148	132	114	101	90	72	66
Receivables	0.4	–	–	–	0.5	0.5	–	–	0.0	–	–	–	0.6	–	–	–	0.8	–	–	–	0.1	–	–	–	–	–	–	7.0	2.3	3.1	1.7	1.1	0.4	2.2	2.0	2.0	1.9	–
Inventory	–	–	–	–	–	–	0.0	0.0	–	–	–	–	–	–	–	–	–	–	–	–	2.5	–	–	–	–	–	–	4.4	–	–	–	–	0.5	–	–	–	–	–
Property, Plant & Equipment	0.9	–	–	–	1.5	3.6	4.8	4.7	4.6	9.0	8.7	8.4	8.1	7.8	7.5	3.7	3.4	3.2	6.0	3.0	3.3	3.0	3.5	3.4	3.4	4.7	13	–	–	–	–	–	–	–	–	–	–	–
Goodwill	–	–	–	–	–	–	0.0	0.0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Intangible Assets	–	–	–	–	–	–	0.0	0.0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Total Liabilities	0.7	–	–	–	80	6.8	6.3	6.1	5.9	11	11	11	11	12	10	11	11	12	9.8	11	21	20	20	22	30	32	31	33	34	30	29	30	28	22	17	15	6.6	2.8
Current Liabilities	0.7	–	–	–	1.5	4.7	3.6	3.5	3.3	4.8	4.7	5.3	6.0	6.8	5.0	6.2	6.4	7.6	5.9	7.9	8.2	7.0	7.9	9.6	11	14	14	17	18	16	17	20	20	17	14	13	6.6	2.8
Short-Term Debt	–	–	–	–	–	–	–	–	–	0.8	0.8	0.9	0.9	0.9	1.0	1.0	1.0	1.1	1.1	1.2	1.2	1.2	1.3	1.3	2.6	2.7	2.8	2.9	3.0	4.4	5.9	7.3	8.7	8.9	13	12	2.3	1.4
Accounts Payable	0.5	–	–	–	0.5	0.7	1.1	0.7	0.2	1.4	1.0	0.8	0.8	1.6	1.0	1.3	2.4	3.6	1.6	1.5	2.0	1.4	1.9	2.3	2.5	4.1	2.5	3.1	8.3	5.1	2.3	3.5	3.7	2.0	1.2	0.9	0.5	0.3
Long-Term Debt	–	–	–	–	–	–	0.0	0.0	–	6.2	–	–	–	–	–	–	–	–	–	–	9.6	9.7	9.7	9.8	9.8	9.9	10.0	10	10	8.8	7.6	6.3	5.1	3.9	2.6	1.4	–	–
Shareholders' Equity	11	11	–	–	-26	47	119	114	109	102	95	86	78	123	158	150	141	141	130	119	197	232	297	283	270	252	232	216	188	169	151	134	117	103	92	83	70	65
Retained Earnings	-18	–	–	–	-26	-31	-38	-43	-49	-57	-66	-75	-84	-94	-104	-115	-126	-139	-152	-166	-181	-197	-213	-231	-249	-271	-295	-319	-351	-372	-394	-414	-434	-451	-465	-476	-491	-496
Shares Outstanding	–	13	13	13	13	18	18	19	19	19	19	19	19	51	43	50	50	51	52	52	56	61	64	72	72	72	72	73	73	73	73	73	7.3	7.3	7.3	7.3	7.3	7.3

Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings